ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Open-Label AIO Study of Transarterial Chemoembolization + Nivo Performed for Intermediate-Stage HCC: Updated Efficacy Results
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
96 views
June 15, 2022
Comments 0
Login to view comments.
Click here to Login
GI